Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Haemonetics Corp (NY: HAE )

85.05 -0.02 (-0.02%)
Streaming Delayed Price Updated: 1:02 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 58,437
Open 84.07
Bid (Size) 85.00 (2)
Ask (Size) 85.17 (4)
Prev. Close 85.07
Today's Range 83.60 - 85.25
52wk Range 70.74 - 95.26
Shares Outstanding 51,029,618
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
For those who appreciate growth without the sticker shock, NYSE:HAE is worth considering.
For those who appreciate growth without the sticker shock, NYSE:HAE is worth considering. 
Via Chartmill
Earnings Scheduled For February 8, 2024
Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million. 
Via Benzinga

Performance

YTD
-0.11%
-0.11%
1 Month
+3.95%
+3.95%
3 Month
+1.53%
+1.53%
6 Month
-3.17%
-3.17%
1 Year
+0.29%
+0.29%

More News

Read More
Intuitive Surgical Stock Earns Relative Strength Rating Upgrade; Hits Key Benchmark
Via Investor's Business Daily
Intuitive Surgical Stock Rating Climbs As Sales, Profits Rise
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Is HAEMONETICS CORP/MASS (NYSE:HAE) suited for quality investing?
Via Chartmill
Exploring NYSE:HAE's quality characteristics.
Via Chartmill
Should you consider NYSE:HAE for quality investing?
Via Chartmill
4 Analysts Have This to Say About Haemonetics
Via Benzinga
Intuitive Surgical Stock Nearly Doubles; Gets Rating Upgrade
Via Investor's Business Daily
Haemonetics Earnings Preview
Via Benzinga
Haemonetics Corp. (NYSE: HAE) Making Surprising Moves in Monday Session
Via Investor Brand Network
Haemonetics Q4 Earnings Exceed Expectations On Volume And Price Benefits
Via Benzinga
Recap: Haemonetics Q4 Earnings
Via Benzinga
Looking Into Haemonetics's Return On Capital Employed
Via Benzinga
Alphabet To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Wednesday
Via Benzinga
Earnings Preview: Haemonetics
Via Benzinga
Where Haemonetics Stands With Analysts
Via Benzinga
9 Analysts Have This to Say About Haemonetics
Via Benzinga
Incyte, Haemonetics Post Earnings Beats; One Surges Within Buy Zone
Via Investor's Business Daily
How 2022's Biggest Healthcare Gainers Could Fare In 2023
Via MarketBeat
InMode Stock Shows Improved Technical Strength; Hits Key Technical Threshold
Via Investor's Business Daily
Analysts Take Bullish Stance On Haemonetics, Cites Plasma Momentum As Catalyst
Via Benzinga
Haemonetics: Q2 Earnings Insights
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.